Barely Significant
← all excerpts

Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.

J Oncol · 2021 · PMC8486501 · PMID 34603452

Europe PMCDOI
1
hedged sentence
0.0340
closest p · 0.7× alpha
0.0340
boldest claim

The sentences

showed a trendp =0.034actually significant
Previous treatment without bevacizumab showed a trend of effective when combination therapy ( p =0.034).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.